BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial [Reuters]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Reuters
BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial | Reuters Reuters Staff 1 Min Read April 24 (Reuters) - Aldeyra Therapeutics Inc: * ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL * ALDEYRA THERAPEUTICS INC - ENROLLED FIRST PATIENT IN A PHASE 3 CLINICAL TRIAL OF TOPICAL OCULAR REPROXALAP FOR TREATMENT OF ALLERGIC CONJUNCTIVITIS * ALDEYRA THERAPEUTICS INC - LOOK FORWARD TO PRESENTING RESULTS OF ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL IN SECOND HALF OF 2018 OR EARLY 2019 Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved.
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Here's Why You Should Invest in Aldeyra (ALDX) Stock Now [Yahoo! Finance]Yahoo! Finance
- Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics [Yahoo! Finance]Yahoo! Finance
- Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company [Yahoo! Finance]Yahoo! Finance
- ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
ALDX
Earnings
- 8/3/23 - Beat
ALDX
Sec Filings
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- ALDX's page on the SEC website